$4.46
+0.12 (+2.77%)
Open$4.22
Previous Close$4.34
Day High$4.50
Day Low$4.09
52W High$7.75
52W Low$1.31
Volume—
Avg Volume98.8K
Market Cap227.44M
P/E Ratio—
EPS$-2.53
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+169.3% upside
Current
$4.46
$4.46
Target
$12.01
$12.01
$8.14
$12.01 avg
$13.09
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 368.79M | 346.38M | 334.67M |
| Net Income | 5.96M | 4.54M | 4.70M |
| Profit Margin | 1.6% | 1.3% | 1.4% |
| EBITDA | 7.81M | 7.32M | 6.13M |
| Free Cash Flow | 4.41M | 4.25M | 6.96M |
| Rev Growth | +17.9% | -7.3% | +7.0% |
| Debt/Equity | 0.83 | 0.86 | 0.78 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |